Related Experiment Video
Updated: Jul 20, 2026

Depletion of Specific Cell Populations by Complement Depletion
Published on: February 5, 2010
B cell depletion therapy in rheumatic disease
J C W Edwards1, G Cambridge, M J Leandro
1University College London, Centre for Rheumatology, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK. jo.edwards@ucl.ac.uk
Abstract:
B cell depletion therapy was introduced for auto-antibody associated rheumatic disease in 1998. Encouraging pilot studies in rheumatoid arthritis were followed by randomised controlled trials confirming major benefit. Licensing for use in patients unable to benefit from tumour necrosis factor alpha (TNFalpha) neutralising agents is envisaged shortly. Open studies in other disorders, in particular systemic lupus erythematosus (SLE), have also suggested benefit and its use in life-threatening situations is becoming widespread. Toxicity appears to compare favourably with other agents, but respiratory problems may be more common. Repeated therapy is effective, but may lead to hypogammaglobulinemia. Rituximab is currently the main agent used but other agents are in development. Optimal protocols are not well characterised and will probably be different for different conditions.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease I: Introduction
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
